ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 2561

Circulating Proteomic Profiles and Incident Gout Risk: Prospective Cohort Study of >48,000 Men and Women
Abstract Number: 2562

Efficacy and Safety of Tocilizumab in the Treatment of Chronic Inflammatory Forms of CPPD: Retrospective Study of 55 Cases
Abstract Number: 2563

Efficacy and Safety Results of CT-P41 (Proposed Denosumab Biosimilar) Compared to Reference Denosumab in Postmenopausal Women with Osteoporosis: 78-Week Results from Phase 3 Randomized Controlled Trial
Abstract Number: 2564

Providing Optimal and Equitable Osteoporosis Treatment Using a Programmatic Approach -A 20 Year Longitudinal Study
Abstract Number: 2565

A Randomized, Double-blind, Multicenter, Parallel-arm Phase 3 Study to Compare the Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab-1000 and Prolia in Postmenopausal Women with Osteoporosis
Abstract Number: 2566

Detrimental Effects of Proton Pump Inhibitors on Bone Mineral Density Are Not Mediated by Changes in Serum Calcium or Parathyroid Hormone in Patients with Inflammatory Rheumatic Diseases: A Cross-sectional Study
Abstract Number: 2567

Gene Expression in Osteonecrosis of the Femoral Head: A Region-matched RNA-sequencing Study
Abstract Number: 2568

Incidence of First Fracture in RA Is Increasing Faster Than the General Population
Abstract Number: 2569

A Novel Hyperferritinemia Screen to Aid Differentiation of Hyperinflammatory Disorders
Abstract Number: 2570

Comparison of the Clinical Features and Biomarker Profiles of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Systemic Juvenile Idiopathic Arthritis- Associated Lung Disease (SJIA-LD) Cohort to CARRA Registry SJIA Patients Without Lung Disease
Abstract Number: 2571

Trajectories of Physical Function in Children with Juvenile Idiopathic Arthritis: Results from the CAPRI Registry
Abstract Number: 2572

Biomarker-guided Treatment-and-stop-strategy for Recombinant IL-1Receptor Antagonist (Anakinra) in Patients with Systemic Juvenile Idiopathic Arthritis
Abstract Number: 2573

Efficacy and Safety of Ixekizumab in Children with Active Juvenile Psoriatic Arthritis and Enthesitis Related Arthritis (COSPIRIT-JIA): 16-week Results of a Multicentre, Randomised, Open-label Study
Abstract Number: 2574

Tear Biomarkers for Monitoring Disease Activity and Progression of Noninfectious Chronic Anterior Uveitis in Children
Abstract Number: 2575

Can Immunosuppressive Therapy Be Safely Discontinued in Patients with Lupus Nephritis?

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].